BeiGene, Ltd. (BGNE)
After hours:
| Previous close | 162.01 |
| Open | 162.51 |
| Bid | 161.91 x 100 |
| Ask | 162.31 x 200 |
| Day's range | 159.32 - 162.51 |
| 52-week range | 126.97 - 257.72 |
| Volume | |
| Avg. volume | 222,433 |
| Market cap | 17.619B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.45 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 272.52 |
Business WireBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
Insider Monkey20 Countries with the Highest Rates of Stomach Cancer in the World
In this article, we will be taking a look at the 20 countries with the highest rates of stomach cancer in the world. If you do not want to learn about the global cancer trends, head straight to the 5 Countries with the Highest Rates of Stomach Cancer in the World. Overview of the Global […]
Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
